SHARE

PORTON Starts Construction Of Its Facility For Antibodies And ADCs In Shanghai PORTON Starts Construction Of Its Facility For Antibodies And ADCs In Shanghai
17.04.2023

PORTON Starts Construction Of Its Facility For Antibodies And ADCs In Shanghai

PORTON Starts Construction Of Its Facility For Antibodies And ADCs In Shanghai

On April 11, 2023, Shanghai Porton Nova Biologics, Ltd., a wholly-owned subsidiary of Porton Pharma Solutions Ltd., officially launched the construction of its biologics R&D and manufacturing site in the Waigaoqiao Free Trade Zone of Pudong New Area, Shanghai, China. As an important link in Porton's strategic new capability building, the site will provide one-stop CDMO services for early clinical stage process development and pilot scale production of antibodies and antibody-drug conjugates (ADCs) for global biopharmaceutical companies and new drug R&D institutions after being put into use.
PORTON Starts Construction Of Its Facility For Antibodies And ADCs In Shanghai
Mr. Oliver Ju, Chairman and CEO of Porton, Dr. Bo Qiu, Chief Technology Officer of Shanghai Porton Nova Biologics, Ltd. and other company management representatives as well as core members of the biological macromolecule segment attended the ceremony for the start of construction. Mr. Haixia Wu, CEO of Simbay Park, Simbay Group and Mr. Bin Ni, Assistant President of the Fourth Construction Co., Ltd. of China Electronic System Engineering (project owner) and General Manager of the Biomedical Business Group were invited to attend the ceremony and delivered speeches to jointly witness the beginning of construction of Porton's first macromolecule R&D and manufacturing site.
PORTON Starts Construction Of Its Facility For Antibodies And ADCs In Shanghai
The facility is located in the PhaseII of Simbay Park in the Waigaoqiao Free Trade Zone, Shanghai, with a total area of nearly 7,000 m2. The site will be constructed based on guidelines from NMPA, FDA, EMA, ICH and has capacity of process development and GMP production for antibodies and antibody-drug conjugates (ADCs), which can provide global customers with one-stop services from cell line construction, upstream and downstream process development, conjugation process development, formulation process development, analytical method development, technology transfer to GMP DS manufacturing, GMP filling, finish, release tests, stability study and regulatory filing support.
PORTON Starts Construction Of Its Facility For Antibodies And ADCs In Shanghai
The process development platform and manufacturing facility in the site are expected to be successively put into use from the third quarter to the fourth quarter of 2023, and will closely cooperate with the chemical synthesis service of Payload and Linker of Porton Small Molecule Business Segment, give full play to the technical and production capacity advantages of Porton chemical and biologics capacity, and build a one-stop service platform for antibodies and ADCs with differentiation advantages.

We look forward to the smooth completion of the construction and early launch of the site, which will serve the CDMO needs of more biomedical enterprises so that enabling the public's early access to good medicines.

SHARE

PORTON Starts Construction Of Its Facility For Antibodies And ADCs In Shanghai PORTON Starts Construction Of Its Facility For Antibodies And ADCs In Shanghai
Porton Experts Invited To Participate In The University Of Perugia Master PRO-API Program, Aiding In The Training Of Green Process Chemistry Professionals Porton Will Be Participating In Biotech Outsourcing Strategies Events This June Proton At CPhI North America Again Porton 2023 ESG Report Upcoming Porton Shows In Europe And The USA:Shaping Our Future Together Porton Makes Debut At DCAT Week 2024 To Jointly Promote Industry Development Join Our Founder And CEO @ DCAT Week Porton Pharma Solutions Joined The SBTi To Drive Climate Action Farewell To 2023, And WE Are Sailing Forward To 2024 The Pharma Crystallization Summit (PCS) Is Held Annually To Bring Together Developers Of New Medicines With Crystallization Challenges And The Crystallization Experts (Solution Providers) In The Industry And Academia. Porton Gets Improved In The 2023 S&P Global ESG Score Porton Pharma Solutions Announces New Flagship Facility Offering Integrated API Crystallization And Drug Product Development Services Pharma Digital Intelligence Summit Will Be Held On 5th, September, 2023 [Important Notice] Porton Announcement Regarding The Change Of Email Domain Porton Unveils Its Small Molecule Platform Headquarters In Shanghai PORTON Starts Construction Of Its Facility For Antibodies And ADCs In Shanghai Porton At DCAT Week 2023: A Highly Successful And Strategic Event Porton Released 2022 CSR Report Porton Delivers Strong 2022 Performance With 127% Sales Growth Porton Gets Above-Average S&P Global Environmental, Social, And Governance (ESG) Score
News

Insights Unveiled: Delve into Our Global News Hub!

22.05.2024

Porton Pharma Solutions embark on the next frontier in Mengeš, Slovenia

  • Opening ceremony of the state-of-the-art research and development laboratories for active pharmaceutical ingredients, small molecules, of Porton in Mengeš

  • A donation of EUR 20,000.00 to the municipality of Mengeš for the restoration of a flooded kindergarten

  • New jobs and further growth in the field of API's small molecules in Slovenia, Mengeš

Read the news

Cookie settings

Your current status

Show details